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Abstract 
Objective: To identify potential biomarkers to distinguish familial Mediterranean fever (FMF) from sepsis.
Method: We recruited 28 patients diagnosed with typical FMF (according to the Tel Hashomer criteria), 22 patients 
with sepsis, and 118 age‑matched controls. Serum levels of 40 cytokines were analyzed using multi‑suspension 
cytokine array. We performed a cluster analysis of each cytokine in the FMF and sepsis groups in order to identify spe‑
cific molecular networks. Multivariate classification (random forest analysis) and logistic regression analysis were used 
to rank the cytokines by importance and determine specific biomarkers for distinguishing FMF from sepsis.
Results: Fifteen of the 40 cytokines were found to be suitable for further analysis. Levels of serum granulocyte‑
macrophage colony‑stimulating factor (GM‑CSF), fibroblast growth factor 2, vascular endothelial growth factor, 
macrophage inflammatory protein‑1b, and interleukin‑17 were significantly elevated, whereas tumor necrosis factor‑α 
(TNF‑α) was significantly lower in patients with FMF compared with those with sepsis. Cytokine clustering patterns 
differed between the two groups. Multivariate classification followed by logistic regression analysis revealed that 
measurement of both GM‑CSF and TNF‑α could distinguish FMF from sepsis with high accuracy (cut‑off values for 
GM‑CSF = 8.3 pg/mL; TNF‑α = 16.3 pg/mL; sensitivity, 92.9%; specificity, 94.4%; accuracy, 93.4%).
Conclusion: Determination of GM‑CSF and TNF‑α levels in combination may represent a biomarker for the differen‑
tial diagnosis of FMF from sepsis, based on measurement of multiple cytokines.
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Introduction
Familial Mediterranean fever (FMF) is an inherited auto-
inflammatory disease clinically characterized by periodic 
fevers with serositis [1, 2]. The gene responsible for the 
disease is the MEFV gene, and the pathogenesis of the 
disease is related to hyperinflammation of inflammas-
omes due to the altered function of the pyrin encoded 
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by the MEFV gene [3–5]. Although there are no specific 
serum biomarkers for the diagnosis of FMF, previous 
reports have shown that serum interleukin (IL)-1β, sol-
uble IL-2 receptor, IL-6, tumor necrosis factor-α (TNF-
α), IL-10, IL-12, IL-17A, and IL-18 are important for the 
pathogenesis of FMF [6–12].
Autoinflammatory diseases, including FMF, are impor-
tant to differentiate from unknown fever. Distinguishing 
FMF from bacterial infections, including sepsis, is diffi-
cult in some cases in daily practice. Delayed diagnosis of 
sepsis often leads to severe conditions, including dissemi-
nated intravascular coagulation, which can be life-threat-
ening due to multiple organ failure. In addition, although 
genetic testing is important for FMF, there are FMF cases 
that do not have the MEFV gene variant.
It has been reported that serum cytokines such as 
IL-1β, IL-6, IL-8, IL-10, IL-12, IL-17A, IL-18, inter-
feron gamma (IFN-γ), and TNF-α are elevated in sepsis 
[13–16], but some of these cytokines are also elevated in 
FMF patients. It is not clear whether existing biomarkers 
are useful in differentiating between these diseases, and 
few studies have compared cytokines in FMF and sepsis 
patients.
To solve this problem, we have attempted to identify 
useful biomarkers for differentiation by comprehensively 
analyzing the serum cytokine profiles of both diseases 
and comparing them in detail using machine learning 
direction including decision tree analysis.
Methods
Patients and controls
This study was registered with the University Hospital 
Medical Information Network Clinical Trials Registry 
(http:// www. umin. ac. jp/ ctr) as UMIN000030922. We 
prospectively recruited consecutive patients with FMF 
who were treated at Nagasaki University, Shinshu Uni-
versity, and Kanazawa University between April 2014 
and March 2019. Diagnosis of FMF was based on the Tel 
Hashomer criteria [17, 18]. We also recruited patients 
with sepsis who were admitted to the Rheumatology 
Department of Nagasaki University Hospital between 
April 2016 and October 2018 and required differential 
diagnoses from fever of unknown origin (FUO). These 
patients did not have any other underlying rheumato-
logical conditions. Sepsis was defined according to the 
Sepsis-3 Criteria—increase in Sequential Organ Failure 
Assessment score of ≥ 2 at day 1 and suspicion of infec-
tion [19]. All participants underwent clinical assessment 
and provided blood samples for analysis at the time of 
admission. The control group was recruited from staff at 
Nagasaki University and residents of the town of Saza in 
Nagasaki Prefecture, as previously described [20].
All patients provided written informed consent for 
participation, and the study and all its protocols were 
approved by the Institutional Review Board of Nagasaki 
University and related centers (Approval No. 18011512-
4). Studies involving residents of Saza were approved by 
the Nagasaki University Ethics Committee for Human 
Use (Approval No. 14051404). Written informed consent 
was obtained from residents of Saza, who underwent 
specific health checkups.
MEFV gene sequencing
MEFV genetic analysis was performed on all patients in 
this study. Promega Wizard® Genomic DNA Purification 
Kit (Promega, Madison, WI, USA) was used to extract 
genomic DNA from blood samples. We subsequently 
performed polymerase chain reaction (PCR) using the 
forward and reverse primers for each exon of the MEFV 
gene, as previously described [21]. We purified PCR 
products with the reagent ExoSAP-IT™ (GE Healthcare 
Japan, Tokyo, Japan) and sequenced directly, using spe-
cific primers and BigDye Terminator v1.1 (Applied Bio-
systems, Tokyo, Japan).
Multiplex cytokine and chemokine bead assays
Serum samples were centrifuged at 3000 × g for 5 min, 
and the supernatants collected and stored at − 80 °C for 
a maximum of 90 days prior to analysis. A blinded mul-
tiplex cytokine bead assay was performed in parallel 
using the Bio-plex MAGPIX™ Human Cytokine Assay 
(Bio-Rad, Hercules, CA, USA) and MILLIPLEX® MAP 
Human Cytokine/Chemokine Magnetic Bead Panel 
1-Premixed 38 Plex (Millipore, Billerica, MA, USA) kits, 
according to the manufacturers’ instructions. Cytokines 
that were frequently found to be at nondetectable lev-
els were excluded from analysis. The multiplex cytokine 
bead assays in this study was done in two times, and we 
calculated the coefficient of variations (CVs) for each 
cytokine using the quality controls samples in the first 
and second times.
Statistical analysis
Baseline demographic characteristics and cytokine/
chemokine levels of the study population were com-
pared using the Kruskal–Wallis test, followed by Dunn’s 
multiple comparisons test. Correlations between pairs 
of serum markers were calculated using Spearman’s rank 
correlation test. To rank the cytokine levels, we per-
formed the multivariate classification algorithm of Ran-
dom Forest analysis (RFA) using the R software package 
RandomForest (http:// cran.r- proje ct. org/ web/ packa ges/ 
rando mFore st/) version 4.6.12, as previously described 
[20]. We subsequently selected a classifier, consisting of 
a combination of cytokine markers that yielded the best 
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classification performance to predict FMF, using multi-
variable logistic regression analysis. We then calculated 
the sensitivity, specificity, accuracy, receiver opera-
tor characteristic (ROC) curve, area under the curve 
(AUC), and Akaike’s information criterion (AIC). Statis-
tical analyses were performed using R software (version 
4.1.0) and JMP pro (version 15.0) (SAS Institute, Cary, 
NC, USA). All reported p values are two-sided, and a p 
value of < 0.05 was considered statistically significant. 
The family-wise error rate in multiple hypotheses testing 
was considered by shrinking the size of a test by dividing 
the original size of a test by the size of the family of the 
tests; the respective applications are stated in the Results 
or footnotes in tables.
Results
Study population
The study population comprised 28 patients with FMF, 
22 with sepsis, and 118 age- and sex-matched healthy 
controls. Table  1 presents the demographic and clinical 
characteristics of the patients with FMF and sepsis. The 
median ages at diagnosis were 40 years and 68 years in 
the FMF and the sepsis groups, respectively. All patients 
with FMF had MEFV genetic testing; the percentage of 
patients with the M694I variant in exon 10 was 39%.
Cytokine profiles of patients with FMF, sepsis, and healthy 
controls
After exclusion of cytokines that were frequently nonde-
tectable, we were able to analyze 15 cytokines: fibroblast 
growth factor 2 (-2), basic granulocyte colony-stimulat-
ing factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), CXCL1 (growth-regulated 
protein alpha precursor [GRO]), IFN-γ, IL-17A, IL-18, 
IL-6, IL-8, CXCL10 (interferon gamma-inducible protein 
10 [IP-10]), CCL2 (monocyte chemoattractant protein-1 
[MCP-1]/MCAF), CCL3 (macrophage inflammatory 
protein-1α [MIP-1α]), CCL4 (macrophage inflammatory 
protein-1β [MIP-1β]), TNF-α, and vascular endothelial 
growth factor (VEGF).
Serum levels of six cytokines were significantly ele-
vated in patients with FMF compared with those with 
sepsis (median FGF-2 73.8 pg/mL vs. 25.7, p < 0.0001; 
median GM-CSF 23.5 pg/mL vs. 1.8 pg/mL, p < 0.0001; 
median IL-17A: 9.9 pg/mL vs. 0.13 pg/mL, p < 0.0001; 
median MIP-1β 60.8 pg/mL vs. 32.4 pg/mL, p = 0.0016; 
median TNF-α 8.6 pg/mL vs. 26.9 pg/mL, p < 0.0010; and 
median VEGF 184 pg/mL vs. 28.6 pg/mL, p = 0.0002) 
(Fig.  1). Among the six cytokines that differed signifi-
cantly between the sepsis and FMF groups, GM-CSF, 
VEGF, FGF-2, and IL-17A were significantly increased 
in the FMF group compared with the control group, 
and TNF-α and MIP-1β were significantly higher in 
the sepsis group than in healthy subjects (Fig.  1). Eight 
cytokines (FGF-2, G-CSF, GM-CSF, IFN-γ, IL-17A, IL-6, 
CXCL10, and VEGF) were significantly increased in the 
FMF group compared with the control group (all p val-
ues are p < 0.0001, Table 2). On the other hand, the lev-
els of five cytokines (G-CSF, IL-6, CXCL10, MCP-1, and 
TNF-α) were significantly higher in the septic group than 
in the control group (p < 0.0001, p < 0.0001, p < 0.0001, 
p = 0.0005, p = 0.0002, respectively, Table  2). The inter-
assay CVs in this study were within 10% for all cytokines, 
which was in close agreement with the CVs provided by 
the manufacturer. The CVs of GM-CSF and TNF-α, two 
particularly important cytokines, were 0.38% and 4.0%, 
respectively.
Comparison of cytokine networks between patients 
with FMF and patients with sepsis
To compare cytokine networks between patients with 
FMF and those with sepsis, we further examined the 
Table 1 The demographic, clinical, and laboratory characteristics of the FMF patients, and the sepsis patients
CRP C-reactive protein; SOFA sequential organ failure assessment; DIC disseminated intravascular coagulation; MAS macrophage activation syndrome. *n = 6, **n = 10
Characteristic FMF patients (n = 28) Sepsis patients (n = 22) Healthy 
controls 
(n = 118)
Age at onset, years 24 (9–48)
Age at diagnosis, years 40 (29–50) 59 (44–71) 56 (47–65)
Female, n (%) 19 (68) 12 (54) 11 (58)
Serum CRP, mg/L 63 (44–99)* 116 (99–148)**
SOFA score 3 (2.8–4.3)
DIC, n (%) 0 (0) 3 (18)
MAS, n (%) 0 (0) 0 (0)
M694I mutation, n (%) 11 (39)
Typical FMF, n (%) 21 (75)
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correlations between serum levels of individual cytokines 
in patients with FMF and in patients with sepsis. We 
found significant correlations between FGF-2 and GM-
CSF (ρ = 0.755, p < 0.0001), FGF-2 and VEGF (ρ = 0.500, 
p < 0.0001), FGF-2 and MIP-1β (ρ = 0.457, p < 0.0001), 
MIP-1β and GM-CSF (ρ = 0.412, p < 0.0001), TNF-α and 
IP-10 (ρ = 0.406, p < 0.0001), and TNF-α and MIP-1β 
(ρ = 0.240, p = 0.0020) in the FMF group.
In the sepsis group, significant correlations were found 
between IL-8 and MIP-1α (ρ = 0.549, p < 0.0001), TNF-α 
and MIP-1α (ρ = 0.374, p < 0.0001), MIP-1α and IFN-γ 
(ρ = 0.367, p < 0.0001), and TNF-α and IFN-γ (ρ = 0.234, 
p = 0.0021). Hierarchical clustering with heatmaps based 
on the Spearman’s rank correlation test is shown in 
Fig.  2A (for the FMF group) and Fig.  2B (for the sepsis 
group). Considering the correlation coefficients, we con-
structed a circular network layout as shown in Figure 2C, 
D. Compared to the sepsis group (Fig.  2C), the FMF 
group (Fig. 2D) showed more complex crosstalk between 
the molecular species in the network with strong correla-
tion edges.
These results suggest that cytokine networks in patients 
with FMF differ from those in patients with sepsis. Thus, 
in the FMF group, FGF-2, GM-CSF, MIP-1β, and TNF-α 
form interrelated networks, whereas in the sepsis group, 
IFN-γ, TNF-α, IL-8, and MIP-1α form interrelated 
networks.
Identification of combinational biomarkers 
for the differential diagnosis of FMF from sepsis by RFA 
and logistic regression analysis
The results of ranking of cytokines by importance, 
according to RFA, are illustrated in Fig. 1C. GM-CSF and 
TNF-α were extracted as the most important cytokines 
for distinguishing FMF from sepsis (mean decrease 
accuracy 14.7 and 9.7, respectively). The results of mul-
tivariable logistic regression analysis and ROC curves 
for sensitivity, specificity, accuracy, AUC, and AIC are 
Fig. 1 A multiplex cytokine bead assay of GM‑CSF, TNF‑α, VEGF, MIP‑1β, FGF‑2, and IL‑17A in the serum of patients with FMF and sepsis. Data are 
presented as individual plots (median, interquartile range). ***p < 0.001, **p < 0.01. GM‑CSF, granulocyte‑macrophage colony‑stimulating factor; 
TNF‑α, tumor necrosis factor‑α; VEGF, vascular endothelial growth factor; MIP‑1β, macrophage inflammatory protein‑1b; FGF‑2, fibroblast growth 
factor 2; IL‑17A, interleukin‑17; FMF, familial Mediterranean fever
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shown in Table 3 and Fig. 3A–C. The best combination 
of cytokines to distinguish FMF from sepsis was found 
to be GM-CSF and TNF-α, with high accuracy observed 
(sensitivity 93%, specificity 94%, and accuracy 93%; 
Table 3). We selected these variables for a logistic regres-
sion analysis and identified independent prognostic fac-
tors of FMF, as follows: GM-CSF (1.0-unit increase, odds 
ratio [OR] = 1.56, 95% confidence interval [CI] 1.05–2.32, 
p < 0.0001) and TNF-α (1.0-unit increase, OR = 0.77, 
95%CI 0.59–1.01, p = 0.0003). After adjusting for the 
effect of age on cytokines by adding age as an explanatory 
factor, the results were similar for sensitivity, specificity, 
and positive detection rates for each cytokine combina-
tion (Supplementary Table 1).
Discussion
We have previously shown that the combination of serum 
IL-18 and FGF-2 is a useful biomarker to discriminate 
between sepsis and adult-onset Still’s disease (AOSD) 
[20]. By adapting a similar approach to FMF patients, 
we extracted GM-CSF and TNF-α as biomarkers that 
discriminate between FMF and sepsis. Although both 
FMF and AOSD are classified as autoinflammatory dis-
eases and the elevated cytokines and pathophysiology are 
partly similar [22, 23], it was surprising that the results 
of extracted cytokines were different between AOSD 
and FMF patients. When comparing FMF and AOSD, 
elevated IL-18 was characteristic of AOSD [23–26]; this 
difference in IL-18 levels may have been reflected in the 
results of the different cytokine combinations in the two 
diseases.
In the present study, serum GM-CSF was significantly 
lower in sepsis patients compared with healthy controls. 
Consistent with the results of this study, plasma GM-CSF 
in sepsis is significantly lower in the nonsurvivor group 
than in survivors and healthy controls [27]. In septic 
patients, GM-CSF has also been shown to act protec-
tively by restoring or improving human monocyte func-
tion, and administration of GM-CSF in mice has been 
shown to prevent abdominal sepsis [28–30]. Although 
the detailed mechanism by which GM-CSF production is 
reduced by bacterial infection has not been established, it 
is interesting to note that these changes contrast with the 
levels in FMF patient sera.
The cytokine profile of FMF is based on aberrant 
activity of inflammasomes. Because of the production 
of IL-1 and IL-18 by macrophages and neutrophils, T 
cells and vascular endothelial cells are activated, result-
ing in a diverse cytokine pattern. In this study, GM-
CSF levels were significantly higher in FMF patients 
than in sepsis patients and healthy subjects. GM-CSF 
is secreted by various cells, including macrophages, T 
cells, and vascular endothelial cells, which may be dif-
ferent from the pathogenesis of sepsis. It has been 
recently reported that GM-CSF activates inflammas-
omes in THP-1 cells and human neutrophils via JAK2 
signaling, which may reflect the pathogenesis of FMF 
[31]. In this study, in addition to serum GM-CSF, 
Table 2 Cytokine profile of FMF patients, sepsis patients, and healthy controls
Values are the median (interquartile range) pg/ml. p values were established using Kruskal-Wallis test followed by a Dunn’s multiple comparisons test. FGF fibroblast 
growth factor; GM-CSF granulocyte-macrophage colony-stimulating factor; GRO growth-regulated protein alpha precursor; G-CSF granulocyte colony-stimulating 
factor; IL interleukin; MCP-1 monocyte chemoattractant protein-1; TNF-α tumor necrosis factor-alpha; VEGF vascular endothelial growth factor. Bonferroni’s correction 
for multiple-cytokine testing was applied and p < 0.0033 was considered significant
FMF Sepsis HCs p value
Median 25th 75th Median 25th 75th Median 25th 75th FMF vs. sepsis Sepsis vs. HCs FMF vs. HCs
FGF-2 73.8 53.1 108 25.7 0 34.1 37.7 21.2 52.2 < 0.001 0.016 < 0.001
G-CSF 36.9 22.5 75.0 41.2 10.4 149 8.2 0 23.0 0.99 < 0.0001 < 0.0001
GM-CSF 23.5 10.8 46.6 1.8 0 3.2 1.5 0 6.7 < 0.001 0.41 < 0.0001
GRO 1193 679 1521 967 516 1453 969 750 1204 0.63 0.99 0.22
IFN-g 15.4 7.2 52.6 4.1 0.8 20.8 4.6 1.3 9.8 0.0313 0.98 < 0.0001
IL-17A 9.9 2.9 33.9 0.13 0 2.8 1.93 0.1 5.8 < 0.001 0.11 < 0.0001
IL-6 23.7 5.5 49.0 34.7 0.7 61.1 0 0 0 0.71 < 0.0001 < 0.0001
IL-8 33.1 16.0 44.5 30.8 13.3 55.4 63.03 23.5 108 0.94 0.031 0.048
IP-10 333 185 950 2083 542 4212 271.68 221 352 0.049 < 0.0001 < 0.0001
MCP-1 453 318 752 1263 805 1708 656 526 837 0.015 0.0005 0.023
MIP-1a 10.9 0.2 16.4 6.8 0 24.5 12.4 0 27.8 0.89 0.53 0.28
MIP-1b 60.8 45.1 74.8 32.4 1.0 46.0 53.2 31.1 79.4 0.0016 0.0077 0.69
TNF-α 8.6 5.7 15.7 26.9 16.7 73.9 12.4 9.3 16.6 0.0010 0.0002 0.055
VEGF 184 141 472 28.6 0 151 88.5 26.6 200 0.0002 0.083 < 0.0001
IL-18 94.2 50.6 772 105 75.1 382 112 65.2 181 0.84 0.86 0.71
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MIP-1β was significantly higher in FMF patients than 
in septic patients. This result may reflect the activation 
of macrophages in FMF, which may reflect inflamma-
tion during the attack period. Considering that FMF 
promotes activation of inflammasomes due to dysfunc-
tions of pylin protein, it is suggested that macrophages, 
the cells most associated with inflammasomes, are 
activated during the attack phase of FMF. However, 
although a previous report has shown that GM-CSF is 
significantly higher in the attack phase than in remis-
sion phases of FMF [6], there is no difference in MIP-1β 
between the previous report and the results of this 
Fig. 2 Cytokine networks in the patients with FMF and sepsis. Hierarchical clustering with a Spearman’s rank correlation heatmap of serum 
cytokine levels among patients with A sepsis and B FMF. Serum circular network layouts in C sepsis and D FMF. Significant correlations (p < 0.0033) 
were represented by connecting edges to underscore strong positive (ρ > 0.50; thick black line), moderate positive (0.3 < ρ < 0.5; thin black 
line). E Cytokines ranked by their relative importance for discriminating FMF from sepsis. The horizontal axis represents the average decrease in 
classification accuracy. FMF, familial Mediterranean fever
Table 3 ROC curve in each subset determined by univariate/multivariable logistic regression analysis
Bold indicates the minimum number of cytokines among the subsets. AIC Akaike’s information criterion; AUC area under the curve; GM-CSF granulocyte-macrophage 
colony-stimulating factor; TNF-α tumor necrosis factor-alpha; VEGF vascular endothelial growth factor
Variables (FMF vs. sepsis) Sensitivity Specificity Accuracy AUC AIC Cutoff value (pg/mL or 
predicted probability*)
GM‑CSF 0.86 0.94 0.89 0.95 30.3 8.3
TNF‑α 0.82 0.78 0.80 0.82 62.7 16.3
VEGF 0.90 0.75 0.82 0.83 54.3 67.1
GM‑CSF + TNF‑α 0.93 0.94 0.93 0.98 19.3 0.75*
GM‑CSF + VEGF 0.86 0.94 0.89 0.94 32.3 0.61*
TNF‑α + VEGF 0.93 0.83 0.89 0.91 42.4 0.55*
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study [6]. In the present study, MIP-1β was significantly 
lower in patients with sepsis than in healthy subjects, 
but the mechanism of this is not clear and should be 
investigated in the future.
There have been several studies on sepsis in which 
serum cytokines have been analyzed. It was reported that 
the cytokines IL-1β, IL-4, IL-6, IL-8, MCP-1, and G-CSF 
had good accuracy for predicting early mortality (< 48 h), 
and IL-8 and MCP-1 had the best accuracy for predicting 
mortality at 28 days [13]. In addition, serum cytokine lev-
els of IL-1β, IL-6, IL-8, IL-10, IL-12, IL-17A, IL-18, IFN-
γ, TNF-α, and calprotectin were found to be elevated in 
sepsis [14, 16, 32]. The levels of cytokines IL-1β, IL-6, 
IL-8, MCP-1, and IL-10, and of plasminogen activator 
inhibitor 1 (PAI-1), were reported to be increased over 
the acute phase and that IL-6, IL-8, MCP-1, and IL-10 
formed a cytokine network in the acute phase of sepsis 
[15]. The results of the present study were consistent with 
previous reports, in that IL-6, IL-8, MCP-1, G-CSF, IFN-
γ, and TNF-α were higher than in healthy subjects, but 
IL-18 and IL-17A were not significantly different between 
healthy subjects and sepsis patients.
In the present study, serum TNF-α levels in patients 
with FMF during attacks were not significantly different 
than those in healthy subjects. Comparing these results 
with previous cytokine analyses using patient sera during 
the attack phase of FMF, there are reports that there is no 
difference in TNF-α levels in FMF patients compared to 
healthy subjects [6, 7], while there are also reports that 
serum TNF-α is elevated in FMF [9]. Since TNF inhibi-
tors are effective in FMF patients, it is quite possible that 
TNF-α reflects the pathogenesis of FMF, but in this study, 
we could not detect any significant difference in serum. 
As for the elevation of TNF-α in septic patients, the 
results were elevated in this study, as well as in previous 
reports.
Serum GM-CSF levels have been shown to be lower 
in the elderly [33]. In the present study, there were 
more elderly patients with sepsis than those with FMF, 
so the possibility of an age effect cannot be ruled out. 
On the other hand, other cytokines that were signifi-
cantly different between the two groups (TNF-α, VEGF, 
FGF-2, MIP-1β, and IL-17A) were not affected by age 
[33].
The strength of this study is that it is, to the best of 
our knowledge, the first to identify clinically important 
serum biomarkers useful for differentiating sepsis from 
FMF, using a Japanese cohort in which all patients were 
genetically tested. However, it should be recognized 
that there are several limitations of this study. Because 
of its cross-sectional design, serial serum samples were 
not used. A validation cohort for the random forest 
analysis was not designed in this study. The cytokine 
combinations identified in this study using machine 
learning will need to be validated in another cohort in 
the future. Although the biomarker may be useful in 
differentiating FMF from sepsis, it may not reflect ther-
apeutic effect or disease activity. Furthermore, since the 
present study included patients who were hospitalized 
for evaluation of FUO and subsequently diagnosed with 
sepsis, the cytokine profile of our septic patients may 
differ from that in the normal population. Therefore, 
future studies with a larger number of septic patients 
should be conducted. Finally, although the efficacy of 
IL-1 inhibitors in patients with severe FMF has been 
shown [34], serum IL-1β levels in the assay we used 
were not high enough to detect significant differences 
in FMF or septic patients.
Fig. 3 ROC curve analysis for the prediction of FMF by a specific set of cytokines. A The combined measurement of GM‑CSF and TNF‑α. B 
The combined measurement of GM‑CSF and VEGF. C The combined measurement of TNF‑α and VEGF. GM‑CSF, granulocyte‑macrophage 
colony‑stimulating factor; TNF‑α, tumor necrosis factor‑α; VEGF, vascular endothelial growth factor
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Conclusions
In conclusion, this study showed that GM-CSF and 
TNF-α can be useful biomarkers for the differential 
diagnosis of FMF and sepsis when measured in combi-
nation. The cytokines that showed contrasting changes 
in sepsis and FMF will not only provide important 
insights into the pathogenesis of both diseases and the 
creation of therapeutic agents, but will also improve the 
ability to diagnose FMF in daily practice.
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